Registration Header
REGISTER TODAY!

Impel NeuroPharma Virtual KOL Event

Start Date:8/6/2021

Start Time:12:00 PM CDT

Duration:120 minutes

Abstract:

We are pleased to have you join us for a virtual presentation which will highlight the post triptan failure landscape and new options for the treatment of acute migraine, the role of non-oral acute migraine therapies, including dihydroergotamine (DHE) history and STOP301 trial results for Impel’s lead product candidate TRUDHESA™, and commercial insights and opportunities in the acute migraine market.

If you're already registered for the Impel NeuroPharma Virtual KOL Event webcast, click below:

ALREADY REGISTERED?

Speakers

Dr. Wade Cooper

Director of Headache and Neuropathic Pain at the University of Michigan School of Medicine

University of Michigan School of Medicine

Dr. Wade Cooper is the Director of Headache & Neuropathic Pain at the University of Michigan where he is also a Clinical Associate Professor in Neurology and Anesthesiology. Dr. Cooper holds a United Council for Neurologic Subspecialties (UCNS) board certification in Headache Medicine. Dr. Cooper has published numerous articles and medical textbook chapters. He serves on the Editorial Board for Headache, the official Journal of the American Headache Society. What drew Dr. Cooper into the field of headache medicine was the immense unmet need and lack of patient access to high quality care.

Dr. Stewart Tepper

Director of Dartmouth Headache Center at the Geisel School of Medicine

Dartmouth Headache Center at the Geisel School of Medicine

Dr. Stewart Tepper, MD is a Neurology Specialist in Lebanon, NH and has over 42 years of experience in the medical field. Dr. Tepper has extensive experience with Headaches. He graduated from Joan Sanford I Weill Medical College Of Cornell University medical school in 1979. He is affiliated with Dartmouth - Hitchcock Medical Center.

Dr. Nada Hindiyeh

Assistant Professor of Neurology and Neurological Systems at Stanford Medical School

Stanford Medical School

Nada Hindiyeh, M.D., is a board-certified neurologist and a clinical assistant professor in the department of Neurology. She was awarded the 2013 Clinical Research Fellowship in Neurotoxins by the American Academy of Neurology and under this scholarship is currently investigating a diagnostic screening protocol for chronic migraine. Other research interests include pathophysiology and novel treatments for migraine, the use of transcranial magnetic stimulation in headache disorders, and participation in clinical trials for new headache therapeutics. She is currently a member of the American Headache Society as well as the International Headache Society. Dr. Hindiyeh completed her medical degree at the University of Toledo College of Medicine in Toledo Ohio. Both her internship and neurology residency were completed at the University of California, Irvine, Medical Center, where she was chief resident. She completed her fellowship in headache and facial pain at Stanford University School of Medicine.

Adrian Adams

Chairman & CEO

Impel NeuroPharma

Adrian has served as Chairman of Impel’s Board of Directors since January 2020 and as Chief Executive Officer (CEO) since May 2020. Prior to this role, Adrian held the position of CEO of Aralez Pharmaceuticals Inc., a pharmaceutical company that focuses on the development, acquisition and commercialization of cardiovascular, pain and other therapies, and was a member of the Aralez Board of Directors from February 2016 to January 2019. He served in this role with the company’s predecessor, POZEN Inc. from May 2015 to February 2016. Prior to joining Aralez, Adrian served as CEO and President of Auxilium Pharmaceuticals, Inc. from December 2011 until its acquisition by Endo International plc in January 2015 for $2.6 billion. Prior to joining Auxilium, from September 2011 until November 2011, Adrian served as Chairman and CEO of Neurologix and President and CEO of Inspire Pharmaceuticals, Inc., where he led the company through a strategic acquisition by global pharmaceutical leader Merck & Co., Inc., for $430 million. Prior to Inspire, Adrian served as President and CEO of Sepracor, Inc., where under his leadership, Sepracor conducted multiple strategic corporate development activities prior to its acquisition by Dainippon Sumitomo Pharma Co for $2.6 billion. Prior to joining Sepracor, Adrian was President and CEO of Kos Pharmaceuticals, Inc. from 2002 until the acquisition of the company by Abbott Laboratories in 2016 for $3.7 billion. Adrian has also held general management and senior international and national marketing positions at Novartis, SmithKline Beecham and ICI (now part of AstraZeneca). He also serves as the Chairman of the Board of Directors at AcelRx Pharmaceuticals, Inc., and Chairman of the Board at Akebia Therapeutics, Inc. Adrian graduated from the Royal Institute of Chemistry at Salford University.
First Name
Last Name
Email Address
Company
Job Title
Country